Return to homepagePandemic Pact

COMBAT - A Combination B-and T-Cell Epitope Vaccine to Futureproof COVID-19 Vaccine

  • Funded by National Health and Medical Research Council (NHMRC)
  • Total publications:0 publications

Grant number: GA202709

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2022
    2025

  • Known Financial Commitments (USD)

    $873,396.17

  • Funder

    National Health and Medical Research Council (NHMRC)

  • Research Location

    Australia

  • Lead Research Institution

    Griffith University

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

We are proposing a vaccine that contains only safe components of the SARS-CoV-2 virus, yet effectively elicits protective immunity. The vaccine works by inducing antibodies capable of preventing the virus from attaching to lung cells, and killer T cells that destroy virus-infected cells. This highly innovative approach will generate a much needed safe and prophylactic 2nd generation modular vaccine, ideal for “vaccine update” that will have a major impact on health and society more generally.